Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity.

Serrels A, Lund T, Serrels B, Byron A, McPherson RC, von Kriegsheim A, Gómez-Cuadrado L, Canel M, Muir M, Ring JE, Maniati E, Sims AH, Pachter JA, Brunton VG, Gilbert N, Anderton SM, Nibbs RJ, Frame MC. · 2015

Read Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity. by Serrels A, Lund T, Serrels B, Byron A, McPherson RC, von Kriegsheim A, Gómez-Cuadrado L, Canel M, Muir M, Ring JE, Maniati E, Sims AH, Pachter JA, Brunton VG, Gilbert N, Anderton SM, Nibbs RJ, Frame MC. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4597190.txt.

Introduction

Alan Serrels and colleagues brought out a 2015 cancer study on focal adhesion kinase, or FAK, a protein that helps tumour cells evade the immune system. Working with squamous cell carcinoma, they asked what FAK does when it sits inside the cell nucleus. The work appeared in Cell and used mouse tumours plus cell experiments.

Nuclear FAK switched on chemokine genes, above all one called Ccl5. Those signals drew in regulatory T cells and wore down the killer T cells that attack tumours, so FAK-bearing tumours kept growing. A drug that blocks FAK, named VS-4718 in the study, cut the regulatory T cells and let killer T cells respond. The findings suggest FAK blockers may work partly by freeing the immune system.

Catalog record

CREATORSerrels A, Lund T, Serrels B, Byron A, McPherson RC, von Kriegsheim A, Gómez-Cuadrado L, Canel M, Muir M, Ring JE, Maniati E, Sims AH, Pachter JA, Brunton VG, Gilbert N, Anderton SM, Nibbs RJ, Frame MC.
YEAR2015
COLLECTIONPAPERS
FORMATTXT
FILE SIZE50 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4597190

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity By Alan Serrels, Tom Lund, Bryan Serrels, Adam Byron, Rhoanne C. McPherson, Alexander von Kriegsheim, Laura Gómez-Cuadrado, Marta Canel, Morwenna Muir, Jennifer E. Ring, Eleni Maniati, Andrew H. Sims Published in: Cell DOI: 10.1016/j.cell.2015.09.001 ABSTRACT Summary Focal adhesion kinase (FAK) promotes anti-tumor immune evasion. Specifically, the kinase activity of nuclear-targeted FAK in squamous cell carcinoma (SCC) cells drives exhaustion of CD8+ T cells and recruitment of regulatory T cells (Tregs) in the tumor microenvironment by regulating chemokine/cytokine and ligand-receptor networks, including via transcription of Ccl5, which is crucial. These changes inhibit antigen-primed cytotoxic CD8+ T cell activity, permitting growth of FAK-expressing tumors. Mechanistically, nuclear FAK is associated with chromatin and exists in complex with transcription factors and their upstream regulators that control Ccl5 expression. Furthermore, FAK’s immuno-modulatory nuclear activities may be specific to cancerous squamous epithelial cells, as normal keratinocytes do not have nuclear FAK. Finally, we show that a small-molecule FAK kinase inhibitor, VS-4718, which is currently in clinical development, also drives depletion of Tregs and promotes a CD8+ T cell-mediated anti-tumor response. Therefore, FAK inhibitors may trigger immune-mediated tumor regression, providing previously unrecognized therapeutic opportunities. INTRODUCTION First described more than a decade ago (Onizuka et al., 1999; Shimizu et al., 1999), regulatory T cells (Tregs) have become recognized as a core component of the immuno-suppressive armory utilized by many tumors to keep the anti-tumor activity of antigen-primed CD8+ T cells at bay. Increased Treg numbers has been associated with poorer survival in ovarian (Curiel et al., 2004), gastrointestinal (Sasada et al., 2003), and esophageal (Kono et al., 2006) cancer. Indeed, the ratio of CD8+ T cells/Tregs correlates with poor prognosis, shifting the balance from anti-tumor immunity toward tumor tolerance (Quezada et al., 2006; Sato et al., 2005; Shah et al., 2011). Through secreting a range of chemokines and cytokines, cancer cells can promote the recruitment of Tregs into tumors and can also facilitate their peripheral expansion and retention (Darrasse-Jèze and Podsypanina, 2013; Ondondo et al., 2013). Thus, Tregs can act as a barrier to effective immune-based therapy aimed at activation of a CD8+ T cell anti-tumor immune response. However, the specific signals within tumor cells that stimulate elevated intra-tumoral Tregs, giving rise to tumor tolerance, remain elusive. FAK is a tyrosine kinase that regulates diverse cellular functions, including adhesion, migration, invasion, polarity, proliferation, and survival (Frame et al., 2010). Using targeted gene deletion in mouse skin, we have previously shown a requirement for fak in tumor initiation and progression to malignant disease (McLean et al., 2004). FAK is also required for mammary tumor progression, intestinal tumorigenesis, and the androgen-independent formation of neuroendocrine carcinoma in a mouse model of prostate cancer (Ashton et al., 2010; Lahlou et al., 2007; Luo et al., 2009a; Provenzano et al., 2008; Pylayeva et al., 2009; Slack-Davis et al., 2009). Expression of FAK is elevated in a number of tumor types (reviewed in McLean et al., 2005), and FAK inhibitors are being developed as potential cancer therapeutics (Roberts et al., 2008; Shapiro et al., 2014). Many of FAK’s functions in cancer are via its role in signaling downstream of integrins and growth factor receptors at the plasma membrane. FAK also contains putative nuclear localization sequences (NLS) within the F2 lobe of its FERM domain and can localize to the nucleus upon receipt of cellular stress, where it binds to p53 (Lim et al., 2008). However, the extent of FAK’s nuclear functions remains largely unknown. Here, we report a function for nuclear FAK in regulating transcription of inflammatory cytokines and chemokines, in turn promoting an immuno-suppressive, pro-tumorigenic microenvironment. This is mediated by recruitment and expansion of Tregs via FAK-regulated chemokine/cytokine networks, and we have found an important role for Ccl5 and TGFβ2. Therefore, FAK controls the tumor environment, and suppressing FAK activity, including via a clinically relevant FAK inhibitor, may be therapeutically beneficial by triggering immune-mediated tumor regression. RESULTS FAK-Deficient SCC Tumors Undergo Regression in an Immune-Competent Host We used a syngeneic model of SCC in which the fak gene had been deleted by Cre-lox recombination (McLean et al., 2004; Serrels et al., 2012) and mutant tumor cell lines generated. We monitored tumor growth following injection of 1 × 106 FAK-deficient cells (FAK−/−) or FAK-deficient cells that re-expressed wild-type FAK (FAK-WT) at comparable levels to endogenous FAK in both CD-1 nude and FVB (syngeneic) host mouse strains. In CD-1 nude mice, SCC FAK−/− tumor growth was characterized by a modest growth delay (Figure 1A) as reported previously (Serrels et al., 2012). By contrast, in FVB mice, SCC FAK−/− tumor growth was characterized by an initial period of growth in the first 7 days followed by complete regression by day 21 (Figure 1B). Thus, FAK expression is required for the survival and growth of SCC tumors in FVB mice with a functional adaptive immune system. SCC FAK−/− Tumor Regression Is Dependent on CD8+ T Cells To characterize the role of adaptive immunity in FAK−/− SCC tumor regression, we used antibody-mediated T cell depletion in animals bearing FAK−/− tumors (Figures 1C and S1). Depletion of CD4+ T cells had no effect on tumor growth. In contrast, depletion of CD8+ T cells, either alone or in combination with CD4+ T cells, restored SCC FAK−/− tumor growth. This implies that cytotoxic CD8+ T cells were responsible for regression of FAK−/− tumors (Figure 1C) but does not exclude an accessory role for CD4+ T cells. T cell depletion in mice bearing SCC FAK-WT tumors (Figure 1D) revealed that: (1) depletion of CD8+ T cells, either alone or in combination with CD4+ T cells, caused a significant increase in tumor growth when compared to isotype-treated controls at day 14, and (2) depletion of CD4+ T cells alone caused regression of FAK-WT SCC tumors by day 21. This implied that FAK-expressing tumors were also under negative pressure from the immune system and that cells from the CD4+ T cell compartment play a role in protecting FAK-WT tumors from immune-mediated regression (reason discussed later; Figure 3). Next, we re-challenged mice with 1 × 106 SCC FAK-WT cells after regression of primary FAK−/− SCC tumors, following 7 days of tumor-free survival after the tumors had regressed (Figure 1E, top and middle graphs). Neither FAK-deficient nor FAK-expressing SCC cells were able to grow after the mice had been pre-challenged with SCC FAK−/− cells. As controls, SCC FAK-WT and FAK−/− cells were injected at day 28 into mice with no pre-challenge, and these grew as expected (Figure 1E, bottom). This implies that, following FAK−/− SCC tumor regression, host mice remain immunized against further tumor challenge because immunological memory had been established. It is possible that either broad immunization against SCCs may have occurred or, more likely, that the FAK−/− and FAK-WT SCCs shared common antigen(s) that are expressed irrespective of FAK status. We conclude that FAK enables SCC cancer cells to suppress an adaptive immune response rather than to circumvent it through evading recognition per se. SCC FAK−/− cells in which a FAK kinase-deficient mutant was re-expressed (SCC FAK-KD) initially grew and then regressed with kinetics that were only modestly delayed when compared to FAK−/− cells, indicating that immune suppression depends on FAK kinase activity

Read the complete text